Consensus on the place in therapy of biologics in the treatment of patients with chronic plaque psoriasis

Burlando, Martina; Baldari, Manuela; Brunasso, Alexandra Maria Giovanna; Cannata, G; Massone, Cesare; Pestarino, A; Stradini, Daniela; Parodi, Aurora

doi:10.23736/s2784-8671.21.06984-4

Cited by 2 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regarding the treatment of moderate‐to‐severe cases, usually systemic disease‐modifying antirheumatic drugs (DMARDs), such as cyclosporine and methotrexate, or acitretin, are needed 3 . When a patient has a contraindication or an incomplete response to conventional DMARDs, biologics are the treatment of choice 4–7 …”

Section: Introductionmentioning

confidence: 99%

“…3 When a patient has a contraindication or an incomplete response to conventional DMARDs, biologics are the treatment of choice. [4][5][6][7] In particular, three selective antagonists of the p19 subunit of IL-23 have been developed (guselkumab, risankizumab and tildrakizumab). 8 Guselkumab is the first human IgG1λ monoclonal antibody that inhibits IL-23 selectively.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Gargiulo

Ibba

Malagoli

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

Background Guselkumab is a fully human monoclonal antibody that binds selectively to the p19 subunit of interleukin‐23, which has shown efficacy in patients with previous incomplete response to ustekinumab in the NAVIGATE clinical trial. [Correction added on [28‐02‐2023], after first online publication: ‘humanized monoclonal antibody’ has been changed to 'fully human monoclonal antibody' in the preceding sentence.] Objectives We conducted a 104‐week multicenter retrospective study to assess the effectiveness and safety of guselkumab in patients affected by plaque psoriasis with an inadequate response to ustekinumab in a real‐life setting. Methods Our retrospective study included 233 adults affected by moderate‐to‐severe plaque psoriasis, enrolled in 14 different Italian centres, and treated with guselkumab after failing therapy with ustekinumab. Patient characteristics and PASI (Psoriasis Area and Severity Index) score at each visit (baseline, weeks 16, 52 and 104) were recorded. The percentages of patients achieving 75%, 90% and 100% (PASI 75, PASI 90 and PASI 100) improvement in PASI, compared with baseline, were registered. Results At week 52, PASI 75 was reached by 89.88% of patients, PASI 90 by 71.43%, PASI 100 by 58.83% and absolute PASI ≤2 by 90.48%. At week 104, similar effectiveness results were observed. Compared to the NAVIGATE trial, we observed higher rates of PASI 75/90/100. Patients with the involvement of difficult‐to‐treat areas were significantly less likely to achieve PASI90 and PASI100 at week 16. Obese patients had significantly lower rates of PASI75 and PASI ≤2 at week 52. At week 104, comparable responses were observed among all patients' subgroups, regardless of BMI status, involvement of difficult‐to‐treat areas, presence of cardiometabolic comorbidities and concomitant psoriatic arthritis. No significant safety findings were reported throughout the study. Conclusion Our data suggest that the efficacy of guselkumab in patients with inadequate response to ustekinumab for plaque psoriasis in ‘real‐life’ clinical practice is comparable with NAVIGATE study with higher percentages of patients achieving PASI90 and PASI100 at weeks 16, 52 and 104.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Gargiulo

Ibba

Malagoli

et al. 2023

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

What Can IBD Specialists Learn from IL-23 Trials in Dermatology?

Valenti

Narcisi

Pavia

et al. 2022

Journal of Crohn's and Colitis

View full text Add to dashboard Cite

Background and Aims The advent of biologic drugs revolutionised the treatment of many chronic inflammatory diseases in rheumatology, dermatology, and gastroenterology. The introduction of different targeted agents closely followed the increase in knowledge of pathogenic mechanisms. The identification of IL-23 as a master regulator of ‘pathogenic’ inflammation and the consequent efficacy of IL-23 blocking agents were first proofed in psoriasis and then in other inflammatory diseases such as psoriatic arthritis and Crohn’s disease. Methods We reviewed all available results from anti-Il-23 clinical trials for psoriasis, focusing on data of IBDologists’ interest. Regarding guselkumab, we analysed data from phase III clinical trials VOYAGE1, VOYAGE2, and NAVIGATE. For risankizumab, we reported efficacy and safety results from UltIMMa-1, UltIMMa-2, and IMMvent clinical trials, and tildrakizumab was evaluated by analysing data from reSURFACE1 and reSURFACE2 studies. Results Data from all the clinical trials that we reported showed both the efficacy of all three anti-IL-23 drugs in psoriasis and the safety of this class; in particular, no gastrointestinal side effects were observed in those studies. IL-23 blockers have shown promising short- and long-term results in psoriasis, with a major safety profile and no negative interactions with gastrointestinal system. Conclusions Anti-IL-23 indication for psoriatic arthritis is very recent and for IBD is still to come. Therefore, dermatologists are accumulating long-term experience with these drugs, both in clinical trials and in real-world evidence, which can help gastroenterologists in the management of IBD patients.

show abstract

Consensus on the place in therapy of biologics in the treatment of patients with chronic plaque psoriasis

Cited by 2 publications

References 5 publications

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO (ITALIAN LANDSCAPE PSORIASIS)

What Can IBD Specialists Learn from IL-23 Trials in Dermatology?

Contact Info

Product

Resources

About